Skip to main content

Table 11 Second-line systemic agents for Sweet's syndrome

From: Sweet's syndrome – a comprehensive review of an acute febrile neutrophilic dermatosis

Indomethacin Administered at a oral daily dose of 150 mg for 7 days, and then 100 mg per day for 14 days [259,261,284,378].
Clofazimine Administered orally at a daily dose of 200 mg for 4 weeks, and then 100 mg per day for 4 weeks [12,296,379].
Cyclosporin As monotherapy or as a second-line agent (after failure of first-line therapy or as a corticosteroid-sparing agent) [12,30,231,294,380,381]. Initial oral daily dose ranged from 2 mg/kg/d [380] to 4 mg/kg/d [231] to 10 mg/kg/d [12,381]; in the latter patient, from the 11th day the dose was reduced by 2 mg/kg/d every 2 days and discontinued on day 21 [12,381].
Dapsone As either monotherapy or in combination therapy. Initial oral dose ranged from 100 mg per day to 200 mg per day; the latter dose was either administered as a single dose or divided into 2 equal doses [17,20,30,203,221,245,284,372,382-384,421].
  1. Source [1]: Adapted with permission from Cohen PR, Kurzrock R: Sweet's syndrome revisited: a review of disease concepts. Int J Dermatol 2003;42:761–778. Copyright 2003, Reprinted with permission from the International Society of Dermatology, Blackwell Publishing Ltd, Oxford, United Kingdom.